soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 NEJM Editorial Fellow Harleen Marwah,

Wegovy pill (oral semaglutide) is the first and only FDA-approved GLP-1 pill for weight loss

Growth hormone receptors have been identified in hair follicle cells, and GH signaling appears to influence the duration and vigor of the anagen phase

For example, in women, chronic cortisol elevation links to lower implantation rates in assisted reproduction

Th nhng, vic chm da trng mn li khng h d dng

Additionally, the growing cases of cardiovascular diseases and obesity are also contributing to their increased demand for GLP-1 drugs

Seek treatment from licensed medical professionals physicians, nurse practitioners, or registered nursesvworking in legitimate medical facilities